Stevens Matthew P, Rudland Elice, Garland Suzanne M, Tabrizi Sepehr N
Department of Microbiology, The Royal Women's Hospital, and Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia.
J Clin Microbiol. 2006 Jul;44(7):2428-33. doi: 10.1128/JCM.02608-05.
Roche Molecular Systems recently released two PCR-based assays, AMPLICOR and LINEAR ARRAY (LA), for the detection and genotyping, respectively, of human papillomaviruses (HPVs). The manual specimen processing method recommended for use with both assays, AmpliLute, can be time-consuming and labor-intensive and is open to potential specimen cross-contamination. We evaluated the Roche MagNA Pure LC (MP) as an alternative for specimen processing prior to use with either assay. DNA was extracted from cervical brushings, collected in PreservCyt media, by AmpliLute and MP using DNA-I and Total Nucleic Acid (TNA) kits, from 150 patients with histologically confirmed cervical abnormalities. DNA was amplified and detected by AMPLICOR and the LA HPV test. Concordances of 96.5% (139 of 144) (kappa=0.93) and 95.1% (135 of 142) (kappa=0.90) were generated by AMPLICOR when we compared DNA extracts from AmpliLute to MP DNA-I and TNA, respectively. The HPV genotype profiles were identical in 78.7 and 74.7% of samples between AmpliLute and DNA-I or TNA, respectively. To improve LA concordance, all 150 specimens were extracted by MP DNA-I protocol after the centrifugation of 1-ml PreservCyt samples. This modified approach improved HPV genotype concordance levels between AmpliLute and MP DNA-I to 88.0% (P=0.043) without affecting AMPLICOR sensitivity. Laboratories that have an automated MP extraction system would find this procedure more feasible and easier to handle than the recommended manual extraction method and could substitute such extractions for AMPLICOR and LA HPV tests once internally validated.
罗氏分子系统公司最近推出了两种基于聚合酶链反应(PCR)的检测方法,即AMPLICOR和线性阵列(LA),分别用于检测人乳头瘤病毒(HPV)和进行基因分型。这两种检测方法推荐使用的手工样本处理方法AmpliLute,可能耗时且费力,并且存在潜在的样本交叉污染风险。我们评估了罗氏MagNA Pure LC(MP)作为在使用这两种检测方法之前进行样本处理的替代方法。使用DNA-I和总核酸(TNA)试剂盒,通过AmpliLute和MP从150例经组织学确诊为宫颈异常的患者收集于PreservCyt培养基中的宫颈刷取物中提取DNA。通过AMPLICOR和LA HPV检测对DNA进行扩增和检测。当我们将AmpliLute提取的DNA与MP DNA-I和TNA提取的DNA进行比较时,AMPLICOR产生的一致性分别为96.5%(144例中的139例)(kappa=0.93)和95.1%(142例中的135例)(kappa=0.90)。AmpliLute与DNA-I或TNA之间分别有78.7%和74.7%的样本HPV基因型谱相同。为了提高LA的一致性,在对1 ml PreservCyt样本进行离心后,所有150个样本均通过MP DNA-I方案进行提取。这种改进方法将AmpliLute与MP DNA-I之间的HPV基因型一致性水平提高到了88.0%(P=0.043),且不影响AMPLICOR的灵敏度。拥有自动化MP提取系统的实验室会发现,该程序比推荐的手工提取方法更可行、更易于操作,并且一旦经过内部验证,可用这种提取方法替代AMPLICOR和LA HPV检测。